treatment modality 1:transcatheter arterial chemoembolization combined with immunotherapy and targeted therapy

Clinical trial of hepatic arterial infusion chemotherapy combined with Sintilimab and Bevacizumab for unresectable liver cancer

Efficacy analysis of transcatheter arterial chemoembolization combined with immunotherapy and targeted therapy in patients at high risk of recurrence after radical surgery for primary liver cancer